Protective effect of antithrombin III against lung and myocardial injury in lower-limb ischemia-reperfusion syndrome
| Autor: | Neophytos Zambas, Charalampos Spyridis, Thomas S. Gerassimidis, Christos D. Karkos, Dimitrios Karamanos, Apostolos Kambaroudis |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Antithrombin III Ischemia Myocardial Reperfusion Injury Lung injury Placebo Systemic inflammation Antithrombins chemistry.chemical_compound Malondialdehyde medicine Animals Rats Wistar Lung Dose-Response Relationship Drug business.industry Myocardium Antithrombin General Medicine Free Radical Scavengers Lung Injury medicine.disease Hindlimb Rats Dose–response relationship Disease Models Animal medicine.anatomical_structure Treatment Outcome chemistry Anesthesia Reperfusion Injury Surgery medicine.symptom Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Annals of vascular surgery. 26(4) |
| ISSN: | 1615-5947 |
| Popis: | Background Restoration of blood flow to an acutely ischemic limb can trigger systemic inflammation. We investigated whether antithrombin III (AT-III) exerts a protective action against remote lung and myocardial injury in an experimental animal model of lower-limb ischemia–reperfusion. Methods Ischemia was induced by lower-limb arterial occlusion for 6 hours in 60 male Wistar rats. Animals were divided into those receiving AT-III (dose, 250 mg/kg) 30 minutes before the reperfusion (group A, n = 30) and those receiving placebo (group B, n = 30). Animals were then sacrificed, and lung and myocardial tissue samples were taken at baseline, 30 minutes, and 4 hours after reperfusion. Levels of malondialdehyde (MDA), a compound used as indirect index of oxygen free radicals, were estimated in lung and myocardium, and the two groups were compared at different time points using the independent sample t test. Results Animals administered AT-III had significantly lower levels of lung MDA compared with the placebo group at baseline and at 30 minutes, but not at 4 hours ( P = 0.001, P = 0.01, and P = 0.9, respectively), indicating a protective action of AT-III against remote lung injury early in the reperfusion phase. With regard to myocardial MDA levels, no statistically significant differences existed between the AT-III and placebo groups at baseline, at 30 minutes, and at 4 hours ( P = 0.07, P = 0.07, and P = 0.2, respectively) after reperfusion. Conclusions In this experimental animal model, AT-III appears to exert a protective effect against remote ischemia–reperfusion injury in the lung tissue, but not in the myocardium. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|